Matsuya R&D Co Ltd
Notice Regarding the Results of the Tender Offer for Our Share Certificates by Omron Healthcare Co., Ltd. and Changes in the Parent Company, Major Shareholders, and Principal Shareholders
Omron Healthcare’s tender offer for Matsuya R&D stock has been successful. The total number of shares targeted for acquisition is 17,567,455, which exceeds the planned acquisition volume of 11,230,300 shares, and the settlement start date is 2026/06/19. After the acquisition, Omron will become the parent company, and Matsuya R&D is planned to be delisted.
Key Figures
- Total number of shares for tender (shares, etc.): 17,567,455 shares
- Planned acquisition volume: 11,230,300 shares
- Settlement start date: 2026-06-19
- Voting rights share (post-takeover): 95.88%
AI要約
Background and Overview
This tender offer is Omron Healthcare Co., Ltd. acquiring shares of Matsuya R&D, and it has been successful as the total number of tendered shares exceeded the lower bound of the planned acquisition volume; the settlement start date and settlement initiation date have been announced. The tender offeror intends to acquire all shares and new stock acquisition rights of Matsuya R&D, and ultimately Matsuya R&D is expected to be delisted.
Impact and Outlook
With the successful tender offer, the position of parent company and major shareholders will transfer to Omron Healthcare. After settlement, the tender offeror is expected to hold a majority of voting rights of all shareholders, and delisting procedures will proceed. At this time, the timing of additional procedures is undecided, but after the settlement start date, procedures will be discussed and promptly disclosed.
Matsuya R&D Co., Ltd.
Company overview · Stock price · Financial data · All IR
